• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Get Out the Clot Campaign Brings Together Leaders and Experts to Improve Patient Care for Venous Thromboembolism

    10/10/24 9:00:00 AM ET
    $PEN
    Medical/Dental Instruments
    Health Care
    Get the next $PEN alert in real time by email

    Campaign is led by prominent medical societies to minimize discrepancies in treating blood clot conditions, such as in pulmonary embolism, where there are often delays in care (up to 26% of patients in one study) and misdiagnosis (up to 53% of patients in one study)1,2

    ALAMEDA, Calif., Oct. 10, 2024 /PRNewswire/ -- The International Society on Thrombosis and Haemostasis (ISTH), National Blood Clot Alliance (NBCA), Penumbra, Inc. (NYSE:PEN), The PERT Consortium™ and Society for Vascular Medicine (SVM) today announced the launch of the Get Out the Clot campaign in advance of World Thrombosis Day on October 13. The campaign is a collaborative educational initiative focused on identifying gaps in patient care related to blood clot conditions, standardizing care and expanding access to the latest innovations to improve patient outcomes.

    Get Out the Clot is a collaborative educational initiative uniting experts in venous thromboembolism (VTE) care to help identify gaps in patient care related to blood clot conditions, including standardizing care and expanding access to the latest innovations to improve patient outcomes.

    "Every October, the ISTH leads the global charge with World Thrombosis Day, shining a spotlight on the critical yet often overlooked condition of thrombosis," said Pantep Angchaisuksiri, M.D., ISTH President. "This year's launch of the Get Out the Clot initiative is a call to action, rallying leaders in the field to combine their expertise and resources to significantly improve the lives of patients affected by blood clots. Together, we can drive change and save lives."

    Venous thromboembolism (VTE), a medical condition characterized by the formation of blood clots in veins, effects up to 900,000 Americans annually leading to approximately 100,000 deaths and up to $10 billion in associated costs.3 VTE encompasses deep vein thrombosis (DVT), the formation of a clot in a deep vein most commonly in the legs, and pulmonary embolism (PE) where a blood clot obstructs flow in one or more arteries in the lung. 

    "Given the incredibly high prevalence of VTE, it is critical that health systems create standardized care paths to help facilitate prompt diagnosis and implementation of appropriate treatment interventions," said Herb Aronow, M.D., MPH, Past President, Society for Vascular Medicine.

    Recognizing a need to standardize the care approach for this patient population, VTE or PE response teams (PERTs) have begun to develop at institutions. These teams streamline care through a collaborative multidisciplinary approach by engaging experts with the knowledge of and access to a broad spectrum of resources and treatments, potentially improving patient outcomes.

    "The Get Out the Clot campaign raises awareness of the critical need for a collaborative approach to care," said Rachel Rosovsky, M.D., MPH, Immediate Past President, The PERT Consortium™. "The PERT Consortium™ is proud to be part of this initiative and we are committed to working together to improve the care and outcomes for patients with blood clot conditions."

    The current standards of care in the treatment of VTE include anticoagulation and clot-dissolving drugs such as thrombolytics. Studies have shown that newer treatments such as computer assisted vacuum thrombectomy and mechanical thrombectomy can remove blood clots quickly while also reducing hospital length of stay, lowering the risk of bleeding or invasive surgery, and improving patient outcomes.  An objective of the Get Out the Clot campaign is to ensure that physicians are aware of and have access to these newer treatments.

    "As a PE survivor who personally experienced delays in diagnosis and initially received the wrong treatment protocol, I understand how devastating these gaps in care can be," said Leslie Lake, volunteer president of the National Blood Clot Alliance. "The Get Out the Clot campaign is a crucial step toward changing that reality. By uniting experts and standardizing care, we can prevent the delays and misdiagnoses that cost lives, ensuring that more people receive the urgent, life-saving treatment they need."

    "At Penumbra, our focus has always been to advance novel technologies to improve patient care worldwide," said James F. Benenati, M.D., FSIR, chief medical officer at Penumbra, the world's leading thrombectomy company. "By working together with these leading organizations in vascular care and advocacy, we hope to gain insights into the existing gaps in patient care and collaborate on solutions to improve patient outcomes."

    Healthcare professionals should visit www.GetOutTheClot.com to learn more about the campaign and help raise awareness of VTE symptoms and treatment options.

    About Get Out the Clot

    Get Out the Clot is a collaborative educational initiative uniting experts in venous thromboembolism (VTE) care to help identify gaps in patient care related to blood clot conditions, including standardizing care and expanding access to the latest innovations to improve patient outcomes. The campaign is led by the International Society on Thrombosis and Haemostasis, National Blood Clot Alliance, Penumbra, The PERT Consortium™, and the Society for Vascular Medicine. The organizations involved with Get Out the Clot believe it is critical that health systems across the United States establish a standard of care for thrombotic conditions to help patients get diagnosed promptly and receive the most appropriate care. For more information about Get Out the Clot, visit GetOutTheClot.com.

    About the International Society on Thrombosis and Haemostasis (ISTH)

    Founded in 1969, the ISTH is the leading global non-profit organization focused on advancing the science and clinical care of thrombosis and hemostasis. With a membership of over 7,000 clinicians, researchers, and educators from more than 110 countries, ISTH is dedicated to improving patient outcomes through cutting-edge research, education, and collaboration. Its world-renowned initiatives include educational and standardization programs, clinical and laboratory guidelines, research endeavors, congresses, and peer-reviewed publications. The Society also spearheads the annual World Thrombosis Day (WTD) campaign, observed on October 13. To learn more, visit www.isth.org or explore WTD at www.worldthrombosisday.org.

    About National Blood Clot Alliance

    Founded in 2003, the National Blood Clot Alliance (NBCA) is the premier not-for-profit organization in the United States dedicated to advancing the prevention, early diagnosis, and successful treatment of life-threatening venous blood clots. NBCA brings together patients, caregivers, healthcare professionals, and advocates to raise awareness and improve the quality of care for those affected by blood clots. With a focus on education, advocacy, and patient support, NBCA's initiatives include patient-centered research collaborations, public awareness campaigns, peer support networks, and comprehensive VTE education. Learn more at www.stoptheclot.org.

    About Penumbra

    Penumbra, Inc., the world's leading thrombectomy company, is focused on developing the most innovative technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism such as pulmonary embolism, and acute limb ischemia. Its broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe with speed, safety and simplicity. By pioneering these innovations, Penumbra supports healthcare providers, hospitals and clinics in more than 100 countries, working to improve patient outcomes and quality of life. For more information, visit www.penumbrainc.com and connect on Instagram, LinkedIn and X.

    About The PERT Consortium™

    The purpose of The PERT Consortium™ is to serve the general public by undertaking activities to advance the status of PE care and promote research in the treatment of pulmonary embolism. Specifically, the Consortium's purpose is to:

    Promote the adoption of the PERT model in healthcare institutions across the United States to ensure the prompt diagnosis and treatment of pulmonary embolism.

    Expand the current body of scientific literature on the diagnosis and treatment of pulmonary embolism through the funding of scientific endeavors.

    Educate the general public and healthcare professionals regarding pulmonary embolism diagnosis, treatment, and care.

    By focusing solely on the entity of pulmonary embolism – its etiology, pathophysiology, prevention, management approach, outcomes of specific treatments, and follow-up pathways – it is the intention of the Consortium to increase awareness of treatment options available to patients with PE, to reduce its incidence worldwide, to improve health outcomes, and to positively influence the impact of this terrible disease.

    About the Society for Vascular Medicine

    The Society for Vascular Medicine is a professional organization that aims to improve the integration of vascular biological advances into medical practice and to maintain high standards of clinical vascular medicine. The Society is distinguished by its emphasis on clinical approaches to vascular disorders. Optimal vascular care is best accomplished by the collegial interaction of a community of vascular professionals, including individuals with expertise in vascular medicine, vascular surgery, interventional radiology, vascular nursing, vascular technology, and other disciplines. The Society recognizes the importance of individuals with diverse backgrounds in achieving ideal standards of research and clinical practice. The Society encourages these individuals to join the Society and to help accomplish its clinical and scientific mission.

    Contact







    Jennifer Heth

    Parinaz Farzin

    Penumbra, Inc.

    Merryman Communications

    [email protected]

    [email protected]

    510-995-9791                         

    310-600-6746

     

    ___________________________

    1 Hendriksen JM;Koster-van Ree M;Morgenstern MJ;Oudega R;Schutgens RE;Moons KG;Geersing GJ; (2017, March). Clinical characteristics associated with diagnostic delay of pulmonary embolism in primary care: A retrospective observational study. BMJ open. https://pubmed.ncbi.nlm.nih.gov/28279993/

    2 Chun Shing Kwok, Chun Wai Wong, Saul Lovatt, Phyo K Myint, Yoon K Loke, Misdiagnosis of pulmonary embolism and missed pulmonary embolism: A systematic review of the literature, Health Sciences Review, Volume 3, 2022, 100022, ISSN 2772-6320, https://doi.org/10.1016/j.hsr.2022.100022. 

    (https://www.sciencedirect.com/science/article/pii/S2772632022000113)

    3 Centers for Disease Control and Prevention. (2023, June). Impact of Blood Clots on the United States Infographic. National Center on Birth Defects and Developmental Disabilities (NCBDDD). https://www.cdc.gov/blood-clots/toolkit/impact-of-blood-clots.html?CDC_AAref_Val=https://www.cdc.gov/ncbddd/dvt/infographic-impact.html. Accessed July 9, 2024.

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/get-out-the-clot-campaign-brings-together-leaders-and-experts-to-improve-patient-care-for-venous-thromboembolism-302272207.html

    SOURCE Get Out the Clot

    Get the next $PEN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PEN

    DatePrice TargetRatingAnalyst
    3/14/2025$320.00Buy
    BofA Securities
    1/21/2025$305.00Buy
    UBS
    12/17/2024$275.00Outperform
    Oppenheimer
    12/11/2024$190.00 → $275.00Equal Weight → Overweight
    Wells Fargo
    9/18/2024$238.00Buy
    Stifel
    9/3/2024$263.00Outperform
    Leerink Partners
    7/31/2024$289.00 → $150.00Overweight → Equal Weight
    Wells Fargo
    7/31/2024$165.00 → $178.00Buy → Neutral
    Citigroup
    More analyst ratings

    $PEN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Penumbra, Inc. to Present at the BofA Securities 2025 Health Care Conference

      ALAMEDA, Calif., April 29, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN) today announced that its management team is scheduled to present at the BofA Securities 2025 Health Care Conference on Tuesday, May 13, 2025. Event:     BofA Securities 2025 Health Care ConferenceDate:       Tuesday, May 13, 2025Time:      6:00pm ET/3:00pm PT A webcast of the presentation can be accessed on the "Events and Presentations" section under the "Investors" tab of the company's website at www.penumbrainc.com.  The webcast will be available on the company's website for at least two weeks followi

      4/29/25 4:30:00 PM ET
      $PEN
      Medical/Dental Instruments
      Health Care
    • Penumbra, Inc. Reports First Quarter 2025 Financial Results

      ALAMEDA, Calif., April 23, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN), the world's leading thrombectomy company, today reported financial results for the first quarter ended March 31, 2025. Revenue of $324.1 million in the first quarter of 2025, an increase of 16.3% or 16.9% in constant currency1, compared to the first quarter of 2024.U.S. Thrombectomy revenue of $187.9 million in the first quarter of 2025, an increase of 25.0% compared to the first quarter of 2024.Income from operations of $40.4 million or operating margin of 12.4% in the first quarter of 2025.Net income

      4/23/25 4:05:00 PM ET
      $PEN
      Medical/Dental Instruments
      Health Care
    • Penumbra, Inc. Schedules First Quarter 2025 Earnings Release and Conference Call for April 23, 2025

      ALAMEDA, Calif., April 3, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN) today announced that it will host a conference call to discuss financial results for the first quarter 2025 after market close on Wednesday, April 23, 2025 at 4:30 PM Eastern Time. A press release with first quarter 2025 financial results will be issued after market close that day. Webcast & Conference Call InformationThe conference call can be accessed live over the phone by dialing (888) 596-4144 (conference id: 6572573), or the webcast can be accessed on the "Events and Presentations" section under the

      4/3/25 4:30:00 PM ET
      $PEN
      Medical/Dental Instruments
      Health Care

    $PEN
    Leadership Updates

    Live Leadership Updates

    See more
    • Get Out the Clot Campaign Brings Together Leaders and Experts to Improve Patient Care for Venous Thromboembolism

      Campaign is led by prominent medical societies to minimize discrepancies in treating blood clot conditions, such as in pulmonary embolism, where there are often delays in care (up to 26% of patients in one study) and misdiagnosis (up to 53% of patients in one study)1,2 ALAMEDA, Calif., Oct. 10, 2024 /PRNewswire/ -- The International Society on Thrombosis and Haemostasis (ISTH), National Blood Clot Alliance (NBCA), Penumbra, Inc. (NYSE:PEN), The PERT Consortium™ and Society for Vascular Medicine (SVM) today announced the launch of the Get Out the Clot campaign in advance of World Thrombosis Day on October 13. The campaign is a collaborative educational initiative focused on identifying gaps i

      10/10/24 9:00:00 AM ET
      $PEN
      Medical/Dental Instruments
      Health Care
    • Omniscient Neurotechnology Appoints Two New Members to Its Board of Directors

      SYDNEY, Australia, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Omniscient Neurotechnology, the brain mapping company creating new possibilities in brain health, today announced the appointment of Barbara Nelson and Surbhi Sarna to its board of directors. Both appointees are visionaries across the biotech, healthcare and technology industries and bring a unique perspective to the company's corporate strategy and growth. They, along with the existing board members, will strategically guide Omniscient as it develops products that unlock new insights into advanced brain care. "Omniscient is a global leader in connectomics, but we have much work ahead of us to scale to our full potential," said Chairma

      10/24/22 8:30:00 AM ET
      $BLZE
      $GSIT
      $PEN
      Computer Software: Prepackaged Software
      Technology
      Semiconductors
      Medical/Dental Instruments

    $PEN
    Financials

    Live finance-specific insights

    See more
    • Penumbra, Inc. Reports First Quarter 2025 Financial Results

      ALAMEDA, Calif., April 23, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN), the world's leading thrombectomy company, today reported financial results for the first quarter ended March 31, 2025. Revenue of $324.1 million in the first quarter of 2025, an increase of 16.3% or 16.9% in constant currency1, compared to the first quarter of 2024.U.S. Thrombectomy revenue of $187.9 million in the first quarter of 2025, an increase of 25.0% compared to the first quarter of 2024.Income from operations of $40.4 million or operating margin of 12.4% in the first quarter of 2025.Net income

      4/23/25 4:05:00 PM ET
      $PEN
      Medical/Dental Instruments
      Health Care
    • Penumbra, Inc. Schedules First Quarter 2025 Earnings Release and Conference Call for April 23, 2025

      ALAMEDA, Calif., April 3, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN) today announced that it will host a conference call to discuss financial results for the first quarter 2025 after market close on Wednesday, April 23, 2025 at 4:30 PM Eastern Time. A press release with first quarter 2025 financial results will be issued after market close that day. Webcast & Conference Call InformationThe conference call can be accessed live over the phone by dialing (888) 596-4144 (conference id: 6572573), or the webcast can be accessed on the "Events and Presentations" section under the

      4/3/25 4:30:00 PM ET
      $PEN
      Medical/Dental Instruments
      Health Care
    • Penumbra, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results

      ALAMEDA, Calif., Feb. 18, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN), the world's leading thrombectomy company, today reported financial results for the fourth quarter and full year ended December 31, 2024. Financial Highlights: Adjusted revenue1 of $321.3 million, excluding the $5.8 million impact of the Italian government's payback provision pertaining to prior years, an increase of 12.9% adjusted2 or 13.0% in adjusted constant currency2 compared to the fourth quarter of 2023.Adjusted revenue1 of $1,200.4 million, excluding the $5.8 million impact of the Italian governme

      2/18/25 4:05:00 PM ET
      $PEN
      Medical/Dental Instruments
      Health Care

    $PEN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CEO and President Elsesser Adam exercised 27,976 shares at a strike of $30.00 and sold $4,818,006 worth of shares (16,650 units at $289.37), increasing direct ownership by 18% to 75,237 units (SEC Form 4)

      4 - Penumbra Inc (0001321732) (Issuer)

      5/9/25 7:35:53 PM ET
      $PEN
      Medical/Dental Instruments
      Health Care
    • Chief Financial Officer Yuen Maggie exercised 900 shares at a strike of $158.30 and sold $598,020 worth of shares (2,000 units at $299.01), decreasing direct ownership by 7% to 14,857 units (SEC Form 4)

      4 - Penumbra Inc (0001321732) (Issuer)

      5/6/25 7:30:45 PM ET
      $PEN
      Medical/Dental Instruments
      Health Care
    • Director Bose Arani sold $3,584,775 worth of shares (12,000 units at $298.73), decreasing direct ownership by 4% to 302,819 units (SEC Form 4)

      4 - Penumbra Inc (0001321732) (Issuer)

      4/29/25 7:34:22 PM ET
      $PEN
      Medical/Dental Instruments
      Health Care

    $PEN
    SEC Filings

    See more
    • SEC Form 10-Q filed by Penumbra Inc.

      10-Q - Penumbra Inc (0001321732) (Filer)

      4/23/25 4:44:54 PM ET
      $PEN
      Medical/Dental Instruments
      Health Care
    • Penumbra Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Penumbra Inc (0001321732) (Filer)

      4/23/25 4:14:52 PM ET
      $PEN
      Medical/Dental Instruments
      Health Care
    • SEC Form DEFA14A filed by Penumbra Inc.

      DEFA14A - Penumbra Inc (0001321732) (Filer)

      4/16/25 4:29:05 PM ET
      $PEN
      Medical/Dental Instruments
      Health Care

    $PEN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Penumbra Inc.

      SC 13G/A - Penumbra Inc (0001321732) (Subject)

      11/14/24 1:22:36 PM ET
      $PEN
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Penumbra Inc.

      SC 13G/A - Penumbra Inc (0001321732) (Subject)

      11/12/24 12:53:28 PM ET
      $PEN
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Penumbra Inc.

      SC 13G - Penumbra Inc (0001321732) (Subject)

      2/14/24 10:03:02 AM ET
      $PEN
      Medical/Dental Instruments
      Health Care

    $PEN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BofA Securities initiated coverage on Penumbra with a new price target

      BofA Securities initiated coverage of Penumbra with a rating of Buy and set a new price target of $320.00

      3/14/25 7:46:38 AM ET
      $PEN
      Medical/Dental Instruments
      Health Care
    • UBS initiated coverage on Penumbra with a new price target

      UBS initiated coverage of Penumbra with a rating of Buy and set a new price target of $305.00

      1/21/25 8:26:37 AM ET
      $PEN
      Medical/Dental Instruments
      Health Care
    • Oppenheimer initiated coverage on Penumbra with a new price target

      Oppenheimer initiated coverage of Penumbra with a rating of Outperform and set a new price target of $275.00

      12/17/24 7:54:12 AM ET
      $PEN
      Medical/Dental Instruments
      Health Care